Photoallergic Reaction in a Patient Receiving Vandetanib for Metastatic Follicular Thyroid Carcinoma: A Case Report

Jennifer Goldstein; Anisha B. Patel; Jonathan L. Curry; Vivek Subbiah; Sarina Piha-Paul


BMC Dermatol. 2015;15(2) 

In This Article


Novel targeted agents have been increasingly developed and tested in clinical trials over the past 5–10 years. In clinical trials, drug reactions cannot always be anticipated and novel side effects can be encountered. Vandetinib is a multikinase inhibitor. Herein, we describe a patient with metastatic follicular thyroid carcinoma who we believe developed vandetanib–associated photoallergic dermatitis while enrolled on a phase 1 clinical trial.